“We were interested in TXA127 because our speculation is that downward regulation of ACE2 through SARS-CoV-2 can lead to an angiotensin deficiency (1-7) and cause the renin-angiotensin signaling axis to tilt toward a pro-inflammatory state. Supplementation with exogenous angiotensin (1-7) with TXA127 has the possibility of opposing this alteration,” said Dr. Jeanine D’Armiento, MD, PhD, Professor of Medicine in Cell and Biophysical Anesthesiology and Physiology at Columbia Vagelos College of Physicians and Surgeons and Director of the Center for Molecular Diseases at Columbia University.
TXA127 is a Mas receptor agonist and has been shown in animal models of lung injury that reduces inflammation, stabilizes endothelial and epithelial barriers and reduces fibrosis.